Overview
- A federal jury in California found Apple infringed a Masimo patent tied to blood‑oxygen technology, citing evidence including workout mode and high heart rate notifications.
- The verdict applies to about 43 million Apple Watch units sold from 2020 to 2022, and Apple says it will appeal, noting the patent expired in 2022.
- The U.S. International Trade Commission has instituted a combined modification and enforcement proceeding focused on Apple’s August 2025 implementation that shifts results to a paired iPhone.
- The review will examine whether Apple causes infringement by selling a watch that performs the disputed functions once paired with an iPhone, with a target decision in roughly six months.
- U.S. Customs and Border Protection previously cleared imports of the redesign, which Masimo is challenging in a separate lawsuit, after a 2023 ITC ruling prompted Apple to disable the feature in U.S. models.